WuXi Biologics (Cayman) Inc. (HKG: 2269)

WuXi Biologics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	9,154	9,670	6,395	9,003	7,096	6,205
Short-Term Investments	340.08	340	304.47	1,148	1,272	458
Trading Asset Securities	35.08	1,234	2,015	975.58	112.47	85
Cash & Short-Term Investments	9,529	11,243	8,714	11,126	8,481	6,748
Cash Growth	9.60%	29.02%	-21.68%	31.20%	25.67%	65.23%
Accounts Receivable	6,179	6,184	5,158	3,273	2,371	1,377
Other Receivables	622.8	490.64	616.59	908.05	349.37	288.18
Receivables	6,802	6,675	5,775	4,181	2,770	1,665
Inventory	1,963	1,766	2,281	1,687	1,084	399.39
Other Current Assets	1,523	1,514	1,700	2,535	1,870	858.93
Total Current Assets	19,817	21,198	18,470	19,530	14,204	9,672
Property, Plant & Equipment	30,776	29,939	25,916	19,756	12,870	6,796
Long-Term Investments	2,808	2,934	2,709	2,203	1,074	452.16
Goodwill	1,530	1,530	1,530	1,530	185.41	185.41
Other Intangible Assets	474.8	511.83	548.78	600.65	391.86	415.85
Long-Term Accounts Receivable	151.62	165.5	109.17	124.49	87.67	-
Long-Term Deferred Tax Assets	479.88	235.78	222.57	220.79	80.14	36.04
Other Long-Term Assets	68.88	60.69	58.88	68.42	70.35	44.57
Total Assets	56,106	56,576	49,564	44,033	28,964	17,602
Accounts Payable	874.53	833.27	794.39	617.78	646	185.81
Accrued Expenses	918.93	805.04	997.89	852.59	532.15	264.72
Current Portion of Long-Term Debt	892.6	576.33	1,321	2,122	767.13	506.11
Current Portion of Leases	192.6	154.98	149.06	103.56	60.71	26.49
Current Income Taxes Payable	451.77	618.88	773.83	557.73	250.89	142.15
Current Unearned Revenue	2,917	3,090	3,379	1,734	664.86	336.4
Other Current Liabilities	560.53	1,558	1,903	2,268	1,577	1,410
Total Current Liabilities	6,808	7,636	9,319	8,256	4,498	2,871
Long-Term Debt	1,264	1,571	1,462	640.51	1,838	1,395
Long-Term Leases	2,218	2,259	1,490	1,429	666.51	266.11
Long-Term Unearned Revenue	1,068	969.23	949.46	876.73	873.69	148.89
Long-Term Deferred Tax Liabilities	107.13	122.54	132.08	124.21	180.89	24.73
Other Long-Term Liabilities	-	-	-	-	7.26	-
Total Liabilities	11,465	12,558	13,351	11,326	8,064	4,706
Common Stock	0.23	0.24	0.23	0.24	0.23	0.21
Additional Paid-In Capital	-	24,489	22,102	27,044	15,950	10,260
Retained Earnings	-	14,978	11,578	7,158	3,769	2,080
Treasury Stock	-	-916.92	-	-2,517	-	-
Comprehensive Income & Other	40,655	1,782	1,367	593.13	845.19	443.87
Total Common Equity	40,655	40,332	35,047	32,279	20,564	12,784
Minority Interest	3,986	3,686	1,166	427.57	334.95	111.74
Shareholders' Equity	44,641	44,018	36,213	32,706	20,899	12,896
Total Liabilities & Equity	56,106	56,576	49,564	44,033	28,964	17,602
Total Debt	4,567	4,561	4,422	4,295	3,332	2,194
Net Cash (Debt)	4,961	6,682	4,293	6,831	5,149	4,555
Net Cash Growth	47.76%	55.66%	-37.16%	32.68%	13.04%	11.51%
Net Cash Per Share	1.15	1.54	0.98	1.54	1.22	1.14
Filing Date Shares Outstanding	4,151	4,223	4,225	4,224	4,085	3,884
Total Common Shares Outstanding	4,151	4,223	4,225	4,224	4,085	3,884
Working Capital	13,008	13,562	9,151	11,274	9,706	6,801
Book Value Per Share	9.79	9.55	8.29	7.64	5.03	3.29
Tangible Book Value	38,650	38,290	32,969	30,148	19,987	12,183
Tangible Book Value Per Share	9.31	9.07	7.80	7.14	4.89	3.14
Land	-	6,195	2,114	2,097	301.16	-
Machinery	-	7,632	6,029	4,997	2,662	2,197
Construction In Progress	-	13,750	15,935	10,873	8,911	3,818
Leasehold Improvements	-	3,357	2,581	1,795	1,305	1,153
Order Backlog	-	146,016	-	86,376	73,930	35,525

Source: S&P Capital IQ. Standard template. Financial Sources.